Antibody pharmacokinetics and pharmacodynamics

Journal of Pharmaceutical Sciences
Evelyn D LoboJoseph P Balthasar


The U.S. Food and Drug administration (FDA) has approved several polyclonal antibody preparations and at least 18 monoclonal antibody preparations (antibodies, antibody fragments, antibody fusion proteins, etc.). These drugs, which may be considered as a diverse group of therapeutic proteins, are associated with several interesting pharmacokinetic characteristics. Saturable binding with target antigen may influence antibody disposition, potentially leading to nonlinear distribution and elimination. Independent of antigen interaction, concentration-dependent elimination may be expected for IgG antibodies, due to the influence of the Brambell receptor, FcRn, which protects IgG from catabolism. Antibody administration may induce the development of an endogenous antibody response, which may alter the pharmacokinetics of the therapeutic antibody. Additionally, the pharmacodynamics of antibodies are also complex; these drugs may be used for a wide array of therapeutic applications, and effects may be achieved by a variety of mechanisms. This article provides an overview of many of the complexities associated with antibody pharmacokinetics and pharmacodynamics.


Dec 1, 1992·Immunological Reviews·J R Adair
Jan 1, 1992·Biotechnology & Genetic Engineering Reviews·A Mountain, J R Adair
Dec 1, 1992·The Journal of Pharmacy and Pharmacology·A E SabouraudJ M Scherrmann
Jan 1, 1992·European Journal of Nuclear Medicine·M JuweidA J Fischman
Dec 1, 1991·Seminars in Arthritis and Rheumatism·C PuttermanM Levy
Dec 1, 1991·DICP : the Annals of Pharmacotherapy·N M AllenJ W Findlay
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C J SpringerR G Melton
Jan 1, 1991·International Archives of Allergy and Applied Immunology·A AarliS Thunold
Apr 1, 1991·International Journal of Cancer. Journal International Du Cancer·A BalsariM Ghione
Jan 1, 1989·Cold Spring Harbor Symposia on Quantitative Biology·N E Simister, K E Mostov
Feb 9, 1989·Nature·D J CaponJ E Groopman
Jan 1, 1989·Journal of Toxicology. Clinical Toxicology·J M ScherrmannJ M Bourre
Jan 1, 1988·Toxicon : Official Journal of the International Society on Toxinology·H FaulstichM Derenzini
Sep 1, 1987·Annals of Emergency Medicine·J B Sullivan
Mar 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·N N TengA I Braude
Mar 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G E GoodmanK E Hellström
Dec 22, 1972·Science·B Berkowitz, S Spector
May 5, 1983·Biochimica Et Biophysica Acta·K S BragmanD Papahadjopoulos
Mar 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·T D HeathD Papahadjopoulos
Aug 1, 1993·Journal of Pharmacokinetics and Biopharmaceutics·N L DaynekaW J Jusko
Oct 1, 1993·Clinical Pharmacology and Therapeutics·M R UjhelyiB J Zarowitz
Jan 1, 1993·Advances in Pharmacology·K D Bagshawe
Jul 1, 1994·Clinical and Diagnostic Laboratory Immunology·K Kuus-ReichelN E Kay
Dec 1, 1995·Toxicology Letters·P R Pentel, D E Keyler
Mar 1, 1996·European Journal of Immunology·V GhetieE S Ward
May 28, 1996·Proceedings of the National Academy of Sciences of the United States of America·R P Junghans, C L Anderson
May 1, 1996·Toxicology and Applied Pharmacology·N A Grene-LerougeJ M Scherrmann
Nov 1, 1996·Clinical and Experimental Immunology·M M NewkirkP Apostolakos
Jul 1, 1997·Nature Biotechnology·V GhetieE S Ward
Jul 1, 1997·The Journal of Allergy and Clinical Immunology·T B CasaleD C Adelman
Jan 13, 1998·Immunology Today·V Ghetie, E S Ward

❮ Previous
Next ❯


Jun 2, 2007·Cancer Chemotherapy and Pharmacology·Vincent A PollackWilliam J LaRochelle
Jan 22, 2008·Cancer Chemotherapy and Pharmacology·Jian-Feng LuJacques Gaudreault
Sep 24, 2013·Cancer Chemotherapy and Pharmacology·Vincent Launay-Vacher
Jul 20, 2007·Journal of Pharmacokinetics and Pharmacodynamics·Amit Garg, Joseph P Balthasar
May 13, 2009·Journal of Pharmacokinetics and Pharmacodynamics·Anshu MaratheDonald E Mager
Jun 26, 2009·Journal of Pharmacokinetics and Pharmacodynamics·Ben-Fillippo KrippendorffWilhelm Huisinga
Jul 23, 2011·Journal of Pharmacokinetics and Pharmacodynamics·Wolfgang F RichterFrank-Peter Theil
Oct 18, 2011·Journal of Pharmacokinetics and Pharmacodynamics·Mayumi HasegawaAmit Roy
Dec 7, 2011·Journal of Pharmacokinetics and Pharmacodynamics·Dhaval K Shah, Alison M Betts
Aug 2, 2012·Journal of Pharmacokinetics and Pharmacodynamics·Lambertus A Peletier, Johan Gabrielsson
Nov 28, 2012·Journal of Pharmacokinetics and Pharmacodynamics·Yanguang Cao, William J Jusko
Sep 24, 2005·Pharmaceutical Research·Donald E Mager, Wojciech Krzyzanski
Sep 30, 2008·Pharmaceutical Research·Atul SalujaYatin R Gokarn
Jun 29, 2012·Pharmaceutical Research·Kedan Lin, Jay Tibbitts
Dec 20, 2012·Pharmaceutical Research·Wojciech KrzyzanskiYow-Ming Wang
Apr 2, 2011·Current Infectious Disease Reports·Leo G Visser
Feb 19, 2005·Current Oncology Reports·Emiliano Calvo, Eric K Rowinsky
Jan 10, 2013·Clinical Pharmacokinetics·Miroslav DostalekManoranjenni Chetty
May 4, 2005·Human Immunology·Feng Jin, Joseph P Balthasar
Jul 16, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Anja Schneider, Eckhard Mandelkow
Nov 20, 2012·Biomacromolecules·Daniel SchweizerAchim Göpferich
Sep 25, 2012·Acta Pharmacologica Sinica·Liang ZhaoDiane D Wang
May 7, 2005·Nature Biotechnology·Wayne A Marasco
Apr 20, 2006·Nature Reviews. Immunology·Paul J Carter
Apr 24, 2010·Nature Reviews. Immunology·Andrew C Chan, Paul J Carter
May 11, 2011·Nature Reviews. Rheumatology·Jagadeesh BayrySrini V Kaveri
Feb 13, 2013·Nature Reviews. Rheumatology·Pauline A van SchouwenburgGerrit Jan Wolbink
Jul 25, 2006·Nature Structural & Molecular Biology·Micah A LuftigAndrea Carfí
Apr 22, 2009·The Analyst·Eric EzanFrançois Becher
Sep 6, 2008·The Journal of Infectious Diseases·Jeffrey M JacobsonWilliam C Olson
Feb 18, 2010·Protein Engineering, Design & Selection : PEDS·T IgawaK Hattori

❮ Previous
Next ❯

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Hereditary Sensory Autonomic Neuropathy

Hereditary Sensory Autonomic Neuropathies are a group of inherited neurodegenerative disorders characterized clinically by loss of sensation and autonomic dysfunction. Here is the latest research on these neuropathies.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Landau-Kleffner Syndrome

Landau Kleffner syndrome (LKS), also called infantile acquired aphasia, acquired epileptic aphasia, or aphasia with convulsive disorder, is a rare childhood neurological syndrome characterized by the sudden or gradual development of aphasia (the inability to understand or express language) and an abnormal electroencephalogram. Discover the latest research on LKS here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Regulation of Vocal-Motor Plasticity

Dopaminergic projections to the basal ganglia and nucleus accumbens shape the learning and plasticity of motivated behaviors across species including the regulation of vocal-motor plasticity and performance in songbirds. Discover the latest research on the regulation of vocal-motor plasticity here.